Immunocore posts Q2 KIMMTRAK sales growth as key melanoma trial nears enrollment target
The company said its Phase 3 TEBE-AM trial is nearing its 540-patient enrollment target, with topline data possible by the end of 2026.
SEC filing
Latest
2 stories